Insomnia Market by Therapy Type [Non-pharmacological Therapy (Hypnotherapy, Cognitive Behavioral Therapy, Medical Devices, and Other Non-pharmacological Therapy) and Pharmacological Therapy (Prescription Sleep Aids and Over-The-Counter Sleep Aids)] - Global Opportunity Analysis and Industry Forecast, 2021-2027

ID: VPR/HC/204 Publishing Year: January 2021 Pages: 65 Format:   


Market Overview:

The Global Insomnia Market was valued at $XXX billion in2019, and it is expected to reach $XXX billion by 2027, registering a CAGR of XX% from 2021 to 2027.Insomnia is a sleeping disorder in which you have problem falling or staying asleep. Symptoms of insomnia may include not feeling well-rested, low stamina, daytime sleepiness, depression, and irritability. This disorder affects millions of people, worldwide. Insomnia is caused due to disturbance in circadian rhythm, chronic pain, hyperthyroidism, psychological stress, and other health conditions. Moreover, disproportionate use of drugs, such as caffeine, alcohol, and nicotine could also lead to Insomnia. Due to the development of technologies and introduction of new medicinal devices there is a boost in the growth of the Global Insomnia Market. Only a few medical devices have been permitted in the recent years such as EBB insomnia therapy, Fisher Wallace Stimulator, and Alpha Stim AID, which are anticipated to have higher penetration due to favorable policies and acceptance of device - drug combination therapies for treating Insomnia.
Segment Overview:

Rising awareness about this disease and growth in penetration of new pharmaceuticals & devices are expected to increase the demand of products for treatment of sleep disorders. Around 9 million patients who are treated with pharmaceuticals are unsatisfied. For this unsatisfied patients, devices or a combination of drugs and devices are observed to deliver suitable results. Positive results through the combination of devices & drugs are expected to increase the revenue growth of the Insomnia Market.

 The Global Insomnia Market is segmented into Therapy Type.

Therapy Type Insights:

The Therapy Type Insights are divided into non-pharmacological and pharmacological therapy. Non-Pharmacological Therapy is further segmented into hypnotherapy, cognitive behavioral therapy (CBTI), medical devices, and other non-pharmacological therapy. Pharmacological therapy is further categorized into prescription sleep aids and over-the-counter sleep aids. Cognitive behavioral Therapy is a highly suggested Therapy for insomnia patients as it can be used with multiple approaches that enable physicians to understand and cure patients. Alternate therapies include exercise, yoga, acupuncture, biofeedback, bright light therapy, music therapy, and aroma therapy. In the pharmacological therapy the prescription sleep aids market is divided into non-benzodiazepines, benzodiazepines, melatonin receptor agonist, and other prescription sleep aids. Generic products are cheaper in price and are negatively affecting the growth of the market. Other prescription sleep aids contain sleep aids such as antipsychotics, chloral derivatives, and tricyclic antidepressants.

Major Key players of Global Insomnia Market:

Eisai, Co. Ltd. (Japan), Merck & Co., Inc. (U.S.), Merck & Co. Inc., Meda Consumer Healthcare Inc. (U.S.), Pfizer, Inc. (U.S.), Sanofi (France), Purdue Pharmaceuticals L.P.,Takeda Pharmaceutical Company Ltd. (Japan), Pernix Therapeutics (U.S.), and Purdue Pharma L.P. (U.S.)

Most of the Global Insomnia Markets are focusing on business expansion to gain higher revenue share through adoption of strategies such as mergers and acquisitions and new product development.

Insomnia Market Key Segments:

By Therapy Type

  • Non-pharmacological Therapy
    • Hypnotherapy
    • Cognitive Behavioral Therapy
    • Medical Devices
    • Other Non-pharmacological Therapy
  • Pharmacological Therapy
    • Prescription Sleep Aids
    • Over-the-counter Sleep Aids

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Republic of South Africa
    • Saudi Arabia
    • Rest of LAMEA

TABLE OF CONTENTS:

CHAPTER 1 MARKET INTRODUCTION

1.1. REPORT OVERVIEW

1.2. SCOPE OF THE STUDY

1.3. PRIMARY MARKET SEGMENTS

1.4. RESEARCH METHODOLOGY

CHAPTER 2 EXECUTIVE SUMMARY

2.1. C-LEVEL EXECUTIVE’S OVERVIEW AND PERSPECTIVES

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE

3.2. PRINCIPAL FINDINGS

3.2.1. Key investment pockets

3.2.2. Leading winning strategies

  3.2.3 Key Player Positioning

3.3. PORTERS FIVE FORCES OF COMPETITIVE ANALYSIS

 3.4. MARKET DYNAMICS

3.4.1. Drivers

3.4.2. Restraints

3.4.3. Opportunities

3.4.4. Impact Analysis

3.5. IMPACT OF COVID-19 ON THIS MARKET

CHAPTER 4 Global Insomnia Market, BY Therapy Type

4.1. SYNOPSIS

4.1.1. Market size and forecast

  4.2. Non-pharmacological Therapy

4.2.1. Hypnotherapy

4.2.2. Cognitive behavioural therapy (CBTI)

4.2.3. Medical devices

4.2.4 Other non-pharmacological therapy

4.3. Pharmacological therapy

4.3.1. Prescription sleep aids

4.3.2. Over-the-counter sleep aids

CHAPTER 5 Global Insomnia Market, BY Geography

5.1 SYNOPSIS

  5.1.1. Market size and forecast

5.2 North America

5.2.1 Key market trends

5.2.2 Competitive scenario

5.2.3 Key growth factors and opportunities

5.2.4 Market size and forecast

5.3 Europe

5.3.1 Key market trends

5.3.2 Competitive scenario

5.3.3 Key growth factors and opportunities

5.3.4 Market size and forecast

5.4 Asia Pacific

5.4.1 Key market trends

5.4.2 Competitive scenario

5.4.3 Key growth factors and opportunities

5.4.4 Market size and forecast

5.5 LAMEA

5.5.1 Key market trends

5.5.2 Key growth factors and opportunities

5.5.3 Market size and forecast

CHAPTER 6 COMPANY PROFILES

6.1. Eisai, Co. Ltd. (Japan)

6.1.1. Company overview

6.2.2. Company snapshot

6.1.3. Product portfolio

6.1.4. Business performance

6.1.5. Key strategic moves and developments

6.2 Merck & Co., Inc. (U.S.)

6.2.1. Company overview

6.2.2. Company snapshot

6.2.3. Operating business segments

6.2.4. Product portfolio

6.2.5. Business performance

6.2.6. Key strategic moves and developments

6.3. Merck & Co. Inc.

6.3.1. Company overview

6.3.2. Company snapshot

6.3.3. Operating business segments

6.3.4. Product portfolio

6.3.5. Business performance

6.3.6. Key strategic moves and developments

6.4. Meda Consumer Healthcare Inc. (U.S)

6.4.1. Company overview

6.4.2. Company snapshot

6.4.3. Operating business segments

6.4.4. Product portfolio

6.4.5. Business performance

6.4.6. Key strategic moves and developments

6.5. Pfizer, Inc. (U.S.)

6.5.1. Company overview

6.5.2. Company snapshot

6.5.3. Operating business segments

6.5.4. Product portfolio

6.5.5. Business performance

6.5.6. Key strategic moves and developments

6.6. Sanofi (France)

6.6.1. Company overview

6.6.2. Company Snapshot

6.6.3. Operating business segments

6.6.4. Product portfolio

6.6.5. Business performance

6.6.6. Key strategic moves and developments

6.7. Purdue Pharmaceuticals L.P

6.7.1. Company overview

6.7.2. Company snapshot

6.7.3. Operating business segments

6.7.4. Product portfolio

6.7.5. Business performance

6.7.6. Key strategic moves and developments

6.8. Takeda Pharmaceutical Company Ltd. (Japan)

6.8.1. Company overview

6.8.2. Company snapshot

6.8.3. Operating business segments

6.8.4. Product portfolio

6.8.5. Business performance

6.8.6. Key strategic moves and developments

6.9. Pernix Therapeutics (U.S.)

6.9.1. Company overview

6.9.2. Company snapshot

6.9.3. Operating business segments

6.9.4. Product portfolio

6.9.5. Business performance

6.9.6. Key strategic moves and developments

  6.10. Purdue Pharma L.P. (U.S.)

6.10.1. Company overview

6.10.2. Company snapshot

6.10.3. Operating business segments

6.10.4. Product portfolio

6.10.5. Business performance

  6.10.6. Key strategic moves and developments


PURCHASE OPTIONS




    ADD TO CART

CONTACT US
CALL US ON
( +91-935-919-4956 )

CONTACT EMAIL
[email protected]
PURCHASE OPTIONS




    ADD TO CART

CONTACT US
CALL US ON
( +91-935-919-4956 )

CONTACT EMAIL
[email protected]